NASDAQ: IVAInventiva Sa Stock
$3.57+0.04 (+1.13%)
Updated Jun 18, 2026
IVA Price
$3.57
Fair Value Price
-$0.16
Market Cap
$689.86M
52 Week Low
$2.85
52 Week High
$7.98
P/E
-1.62x
P/B
-20.8x
P/S
93.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.22M
Earnings
-$416.63M
Gross Margin
100%
Operating Margin
-1,730.94%
Profit Margin
-4,468.1%
Debt to Equity
-9.75
Operating Cash Flow
-$123M
Beta
0.35
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IVA Overview
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IVA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IVA
Ranked#341 of 465
Ranked#341 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important IVA news, forecast changes, insider trades & much more!
IVA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IVA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IVA ($3.57) is overvalued by 2,397.18% relative to our estimate of its Fair Value price of -$0.16 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IVA ($3.57) is not significantly undervalued (2,397.18%) relative to our estimate of its Fair Value price of -$0.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IVA due diligence checks available for Premium users.
Valuation
IVA fair value
Fair Value of IVA stock based on Discounted Cash Flow (DCF)
Price
$3.57
Fair Value
-$0.16
Undervalued by
2,397.18%
IVA ($3.57) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IVA ($3.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.62x
Industry
15.77x
Market
9.47x
IVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-20.8x
Industry
4.95x
IVA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
IVA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IVA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$293.5M
Liabilities
$327.1M
Debt to equity
-9.75
IVA's short-term assets ($284.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IVA's short-term assets ($284.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IVA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
IVA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IVA vs Biotech Stocks
Inventiva Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.